skip to Main Content

Novel Oncolytic Chimeric Orthopoxvirus Causes Regression of Pancreatic Cancer Xenografts and Exhibits Abscopal Effect at a Single Low Dose

Newsfeed image, light gray text on dark gray background
Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes the generation and characterization of a novel oncolytic chimeric orthopoxvirus for the treatment of pancreatic cancer.
Read more . . . 

Back To Top